A 2024 Diabetes, Obesity and Metabolism study on a small-molecule NNMT inhibitor found it dose-dependently limited body weight and fat mass gains, improved oral glucose tolerance and insulin sensitivity, and suppressed hyperinsulinaemia in obese mice (PMID 39161060) [6]
Notably, Illinois adopted legislation in 2024 that requires coverage of certain weight loss and obesity medications in the state employee health plan
Connectomics of bipolar disorder: a critical review, and evidence for dynamic instabilities within interoceptive networks
It regulates blood sugar by boosting insulin secretion, reducing glucagon release, and slowing digestion to promote satiety
It is generally not appropriate for people who are pregnant, planning pregnancy, or breastfeeding, and it should not be combined with other semaglutide or GLP-1 products